Zeynep Eroglu MD
Medical Oncologist, Department of Cutaneous Oncology, Moffitt Cancer Center; Assistant Professor, Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, Florida
Dr. Eroglu is a medical oncologist in the Department of Cutaneous Oncology at Moffitt Cancer Center and an assistant professor in the Department of Oncologic Sciences at the University of South Florida Morsani College of Medicine. Her clinical focus is on treating patients with advanced melanoma and other skin cancers, including basal cell carcinoma and Merkel cell carcinoma, and participating in clinical trials. Dr. Eroglu’s research interests are translational and clinical research in targeted therapies and combination immunotherapeutics for melanoma and other skin cancers, along with development of personalized treatment strategies and biomarkers for patients with melanoma.
Recent Contributions to PracticeUpdate:
- Outcome of Melanoma Patients With Elevated LDH Treated With First-Line Targeted Therapy or PD-1–Based Immune Checkpoint Inhibition
- First-Line BRAF/MEK Inhibitors vs Anti–PD-1 Monotherapy in BRAFV600-Mutant Advanced Melanoma
- Anti-Human Glucocorticoid-Induced Tumor Necrosis Factor Receptor Antibody Alone or With Pembrolizumab in Advanced Solid Tumors
- Cobimetinib Plus Atezolizumab in BRAFV600 Wild-Type Melanoma
- Combining Nivolumab and Ipilimumab With Infliximab or Certolizumab in Patients With Advanced Melanoma
- 2020 Top Stories in Advanced Melanoma: Triplet Therapy in Melanoma
- Combination Immunotherapy for Advanced Uveal Melanoma
- Management of Advanced Melanoma After Progression on Anti-PD1 Therapy
- Combined PD-1, BRAF, and MEK Inhibition in Advanced BRAF-Mutant Melanoma
- Intratumoral Tilsotolimod Plus Ipilimumab for Advanced Melanoma After PD-1 Inhibitor Progression